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Sir,
Mickisch et al (2010) recently reported a comparison of the
costs of managing adverse events resulting from treatment of first-
line metastatic renal cell carcinoma (mRCC) with sunitinib or
bevacizumab plus interferon-a2a across several European coun-
tries. The authors concluded that such costs were lower for
bevacizumab plus interferon-a2a than for sunitinib in a number of
countries, including the United Kingdom.
Given the dramatic change in the treatment landscape for
mRCC, we agree with the authors that economic evaluations
become increasingly important, as decision makers with scarce
resources must choose among several available targeted therapies.
However, we fundamentally disagree that costs associated with
management of adverse events can be decoupled from other
significant factors, most notably, clinical benefit and drug/
treatment cost. The cost of adverse event treatment in RCC is
likely to be less than 2–3% of total costs (Benedict et al, 2009;
Rema ´k et al, 2009; Calvo et al, 2010; Thompson Coon et al, 2010),
depending on the country in question and, therefore, virtually
unimportant for the choice of treatment. Moreover, we disagree
that the two regimens have comparable efficacy, as stated by
Mickisch et al (2010), which flatly contradicts two recently
published meta-analyses that suggest sunitinib provides a superior
progression-free survival (PFS) benefit (Mills et al, 2009;
Thompson Coon et al, 2009).
A UK study by Thompson Coon et al (2010), commissioned and
funded by the Health Technology Assessment program on behalf
of the UK National Institute for Health and Clinical Excellence
(NICE), is used here as an illustrative example of a comprehensive
economic evaluation, as it can be compared with the UK results
from Mickisch et al (2010).
Unlike the analysis by Mickisch et al (2010), in which drug
administration costs and initial drug acquisition costs were not
considered, ostensibly to avoid country-specific confounders in
the analysis, Thompson Coon et al (2010) comprehensively
included drug treatment costs, costs associated with routine
patient follow-up, management of treatment-related adverse
events, diagnosis of disease progression, and best supportive care.
It was shown that the costs associated with treating adverse events
represented less than 1% of total costs due to the low incidence
of severe and costly adverse events. Moreover, sensitivity analyses
showed that the hazard ratios for survival and the drug prices
and utilities associated with treatment were the most important
factors.
There is also evidence to indicate that Mickisch et al (2010)
may have overestimated the costs associated with adverse event
management. For example, according to their analysis, the
cost for treating grade 3/4 thrombocytopenia in the United
Kingdom is h3372 per event; however, the UK National Health
Service (NHS, 2010) reference cost database, a standardized
means of assessing the costs of healthcare in the United Kingdom,
estimates this cost at d1746, or h2012 (OANDA, 2010), approxi-
mately 40% lower.
This clearly shows that adverse event costs should not be
assessed independently of survival benefits and treatment costs
when choosing therapy. In addition, evidence supporting the
clinical efficacy of each regimen suggests that sunitinib has the
strongest data to date as first-line mRCC therapy (Motzer et al,
2009), with a PFS of 11 months and overall survival of more than 2
years (26.4 months).
Furthermore, Benedict et al (2009) recently reported findings
from a cost-effectiveness analysis in which sunitinib was found to
be more effective (e.g., gains of 0.16 quality-adjusted life years) and
less costly (i.e., savings of $67798 over 10 years) than bevacizumab
plus interferon-a2a (as well as sorafenib and temsirolimus), when
indirectly compared as first-line mRCC therapy from a US third-
party payer perspective. And, again, unlike the study by Mickisch
et al (2010), this was a comprehensive analysis, which included
drug treatment costs, costs associated with routine patient follow-
up, management of treatment-related adverse events, diagnosis of
disease progression, and best supportive care. It was subsequently
demonstrated in sensitivity analyses that, although the overall
findings for sunitinib were robust to changes in most parameters,
the results, similar to those for Thompson Coon et al (2010), were
most influenced by the hazard ratios for survival, and the drug
prices and utilities associated with treatments, thus providing
further evidence that management of adverse events, although
important, cannot be used in isolation when making treatment
choices. In addition, comparable findings have been reached in
similar analyses recently reported for patients receiving first-line Published online 14 September 2010
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Finally, it has been suggested that toxicities, such as hypothyr-
oidism and cardiotoxicity, may have been underestimated in the
phase III sunitinib registration trial used in the analyses cited
above, in order to highlight potential concern that the estimates for
adverse event management may not adequately reflect everyday
clinical practice or long-term use of sunitinib (Porta, 2010).
However, this concern has not been borne out in the trial itself, in
which long-term follow-up did not result in cumulative toxicity,
and previously reported quality of life measures favored sunitinib
over interferon (Cella et al, 2008; Motzer et al, 2009). On the
contrary, toxicity with sunitinib has even been shown to be
tolerable and manageable in an expanded access program with a
broad population of more than 4000 mRCC patients, including
subgroups of patients with a traditionally poor prognosis (Gore
et al, 2009).
In summary, this analysis by Mickisch et al (2010) advances a
worthy line of investigation of the targeted therapies in mRCC;
however, it falls short in demonstrating that costs of adverse
event management should be considered in a vacuum or that the
clinical benefit gained with sunitinib is outweighed by such costs.
Instead, this study serves to highlight the importance of conducting
comprehensive cost-effectiveness analyses in order to facilitate
treatment choice.
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